Today, a Director at Pacira Pharmaceuticals (NASDAQ: PCRX), Mark Kronenfeld, bought shares of PCRX for $44.61K.
This recent transaction increases Mark Kronenfeld’s holding in the company by 13.2% to a total of $396.7K. Following Mark Kronenfeld’s last PCRX Buy transaction on November 13, 2017, the stock climbed by 3.5%.
See today’s analyst top recommended stocks >>
Based on Pacira Pharmaceuticals’ latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $84.11 million and quarterly net profit of $2.56 million. In comparison, last year the company earned revenue of $70.93 million and had a GAAP net loss of $19.74 million. Currently, Pacira Pharmaceuticals has an average volume of 294.6K.
Based on 14 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $51.33, reflecting a 11.8% upside. Eight different firms, including Barclays and Jefferies, currently also have a Buy rating on the stock.
In the last 30 days, insiders have sold $74.15K worth of PCRX shares and purchased $44.61K worth of PCRX shares. The insider sentiment on Pacira Pharmaceuticals has been negative according to 32 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pacira Pharmaceuticals, Inc. is a holding company, which engages in the development, commercialization, and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients.
